Flexibility to Choose From 3 FDA-Approved Dosing Regimens for Wet AMD

The recommended dose for EYLEA in Wet AMD is 2 mg administered by intravitreal injection Q4 for the first 3 months, followed by 2 mg Q8.1

Recommended dosing regimen for EYLEA® (aflibercept) Injection in patients  with Wet AMD Recommended dosing regimen for EYLEA® (aflibercept) Injection in patients  with Wet AMD
Trust the #1 prescribed anti-VEGF FDA approved for WET AMD, DME, and  MEfRVO. IBM Truven MarketScan data: number of injections administered  from Q4 2018 through Q3 2019; Data on file

Although not as effective as the recommended Q8 dosing regimen, patients may also be treated with 1 dose Q12 after 1 year of effective therapy. Patients should be assessed regularly.1

Although EYLEA may be dosed as frequently as 2 mg Q4 (≈every 25 days, monthly), additional efficacy was not demonstrated in most patients when EYLEA was dosed Q4 compared with Q8. Some patients may need Q4 (monthly) dosing after the first 12 weeks (3 months).1

Trust the #1 prescribed anti-VEGF FDA approved for WET AMD, DME, and  MEfRVO. IBM Truven MarketScan data: number of injections administered  from Q4 2018 through Q3 2019; Data on file

Q4, every 4 weeks; Q8, every 8 weeks; Q12, every 12 weeks.

Only EYLEA Is Approved to Treat 4 VEGF-Driven Retinal Diseases With 1 Single-Dose–Strength PFS

The pre-filled syringe (PFS) offers a more convenient way to prepare EYLEA for administration when compared with vials1

  • Fewer components to handle
  • Helps eliminate multiple preparation steps

One dosage strength may help1

  • Simplify ordering and billing
  • Streamline inventory management
EYLEA® (aflibercept) Injection For Intravitreal Injection packaging and syringe EYLEA® (aflibercept) Injection For Intravitreal Injection packaging and syringe

Preparation of the single-dose, pre-filled syringe for intravitreal administration

VEGF, vascular endothelial growth factor.

A demonstrated safety profile1

Review safety profile, Button Review safety profile, Button

A library of resources for
you and your patients

Access resources, Button Access resources, Button
Enrollment form for reimbursement process, Icon
Reimbursement Support

Get information about navigating the reimbursement process. Find enrollment forms, learn about PA assistance, and more.

See the details, Button
Product support syringe, Icon
Product Support

Find complete product support—
guiding you through
orders, returns, and more.

Learn how it works, Button
Downloadable resource for HCPs, Icon
Resources

Get the information you
and your patients need
about EYLEA.

See resources, Button
References
  1. EYLEA® (aflibercept) Injection full U.S. Prescribing Information. Regeneron Pharmaceuticals, Inc. March 2021
  2. Data on file. Regeneron Pharmaceuticals, Inc.